Separately, HC Wainwright dropped their price objective on Galectin Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, May 17th.
Shares of NASDAQ:GALT opened at $1.19 on Wednesday. Galectin Therapeutics has a 52-week low of $1.19 and a 52-week high of $4.40. The company has a market capitalization of $70.67 million, a P/E ratio of -2.05 and a beta of 1.64. The company has a 50-day simple moving average of $1.57 and a 200 day simple moving average of $1.98. The company has a debt-to-equity ratio of 79.37, a quick ratio of 4.63 and a current ratio of 3.51.
Institutional investors have recently bought and sold shares of the business. Centaurus Financial Inc. bought a new position in Galectin Therapeutics in the first quarter valued at about $34,000. Virtu Financial LLC bought a new position in Galectin Therapeutics in the fourth quarter valued at about $37,000. Commonwealth Equity Services LLC raised its position in Galectin Therapeutics by 59.2% in the first quarter. Commonwealth Equity Services LLC now owns 26,902 shares of the company’s stock valued at $43,000 after purchasing an additional 10,000 shares during the last quarter. Raymond James & Associates bought a new position in Galectin Therapeutics in the third quarter valued at about $51,000. Finally, Benjamin F. Edwards & Company Inc. raised its position in Galectin Therapeutics by 25.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 29,615 shares of the company’s stock valued at $61,000 after purchasing an additional 6,015 shares during the last quarter. Hedge funds and other institutional investors own 12.35% of the company’s stock.
Galectin Therapeutics Company Profile (Get Rating)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Get a free copy of the StockNews.com research report on Galectin Therapeutics (GALT)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.